The Clorox Company — FY2017 Form 10-K
Business context and reporting period. Clorox manufactures and markets consumer and professional products across Cleaning, Household, Lifestyle and International segments. This filing covers the fiscal year ended June 30, 2017, not a standalone 2016 fourth quarter. The supplied filing text incorporates the detailed MD&A and financial statements by reference but does not include them; some financial details therefore are unavailable here.
Financial performance and key metrics
| Metric | FY2017 | FY2016 | Change or context |
|---|---|---|---|
| Net sales | $5.973 billion | $5.761 billion | Company reported 4% growth |
| Continuing-operations earnings before income taxes | $1.033 billion | $983 million | Up about 5% |
| Diluted EPS from continuing operations | Not stated | Not stated | Company reported a 9% increase |
| Cleaning segment sales | $2.002 billion | $1.912 billion | Up about 5% |
| Household segment sales | $1.961 billion | $1.862 billion | Up about 5% |
| Lifestyle segment sales | $1.000 billion | $990 million | Up about 1% |
| International segment sales | $1.010 billion | $997 million | Up about 1% |
RenewLife, acquired in May 2016 for $290 million, contributed $130 million of global sales in FY2017, compared with $21 million in FY2016. Clorox repurchased approximately 1.5 million shares for $189 million and paid $412 million in dividends. It announced a 5% increase in its quarterly dividend, payable in August 2017.
The filing excerpt does not provide clear FY2017 values for net income, operating income, gross or operating margins, cash flow, cash balances, or current liquidity. It reports more than $2 billion of debt at June 30, 2017; the detailed debt and liquidity metrics are not provided in the excerpt.
Changes versus prior comparable period
- Net sales rose from $5.761 billion to $5.973 billion; reported growth was 4%.
- Pretax earnings from continuing operations increased from $983 million to $1.033 billion.
- All four segments reported higher sales. Household and Cleaning had the strongest dollar growth; International sales remained affected by currency declines and inflation.
- RenewLife sales increased substantially as the acquisition was included for a fuller year in FY2017.
- Raw-material and commodity costs increased, adding pressure despite price increases and cost-saving actions.
Outlook, management commentary, risks and unusual items
For FY2018, management anticipated continued competition, a more competitive retail environment, rising commodity costs and difficult macroeconomic conditions in many international markets. Clorox’s long-term financial goals include annual sales growth of 3%–5%, annual EBIT margin expansion of 25–50 basis points and free cash flow of 10%–12% of net sales; these are goals, not FY2018 guidance.
- Management cited innovation, brand investment, pricing and cost savings as priorities. It reported strong FY2017 results despite competitive pressures, inflation and unfavorable foreign exchange in international markets.
- Key exposures include competition from national and private-label brands, retailer concentration, commodity and transportation costs, foreign exchange and inflation, and reliance on certain suppliers. Walmart and its affiliates represented 26% of FY2017 sales; the five largest customers accounted for nearly half of sales.
- Environmental remediation liabilities were recorded at $28 million at June 30, 2017, versus $14 million a year earlier. Management noted actual exposure could exceed recorded amounts.
- For the Glad business, the estimated fair value of P&G’s 20% interest was $458 million, of which $317 million was recognized as a liability. The agreement was due to expire in January 2023 absent extension or another agreed action; a future purchase obligation and changes in estimated value could affect earnings and cash flow.
- The filing describes Venezuela’s government takeover of Clorox’s former operations and related potential liabilities. Management said routine litigation, based on its analysis, was not expected to have a material adverse effect in aggregate, while noting outcomes cannot be predicted with certainty.
Investor verification priorities
- Review Exhibit 99.1 for audited net income, EPS, margins, cash flows, balance-sheet liquidity, debt maturities and the full FY2017-versus-FY2016 MD&A; those details are absent from the supplied text.
- Assess whether reported sales and EPS growth were supported by underlying volume, pricing, mix and recurring operations, and quantify foreign-exchange effects.
- Check the FY2018 outlook and assumptions for commodity inflation, cost savings, pricing and international markets in the incorporated MD&A.
- Verify the Glad agreement’s status and the amount and timing of any eventual payment to P&G.
- Monitor environmental remediation estimates, litigation and Venezuela-related developments, as well as customer concentration and debt covenant capacity.